Stonegate Capital Partners is hosting a webcast for Palisade Bio (NASDAQ: PALI) to discuss clinical data on LB1148, an investigational treatment of post-surgical abdominal adhesions.
Dallas, Texas--(Newsfile Corp. - March 14, 2022) - Stonegate Capital Partners is hosting a webcast for Palisade Bio (NASDAQ: PALI) to discuss clinical data on LB1148, an investigational treatment of post-surgical abdominal adhesions. The virtual presentation will review the Company’s data being presented at the SAGES 2022 Annual Meeting and the need for new pharmaceutical options to prevent post-surgical abdominal adhesions. The live virtual event will begin Wednesday March 16th 2022 at 8:30 am ET and be available by replay. >> Click here to register or attend.
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- Palisade Bio to present clinical data on LB1148 on prevention of post-surgical abdominal adhesions.
- Ronald Hurst, MD, Principal Investigator of the study and Michael Dawson, MD, to participate in virtual presentation to review data and the need for new options to
- The webinar will be hosted by Stonegate Capital Partners on March 16th at 8:30 am ET.
Click image above to view full announcement.
About Stonegate Capital Partners
Stonegate Capital Partners is a leading advisory firm founded in 1972. We specialize in capital markets advisory with a focus on institutional investor outreach for public and private companies. Our affiliate, Stonegate Capital Markets (Member FINRA/SIPC) provides a full spectrum of investment banking services and equity research.
Contacts:
Erol Girgin
214.987.4121
erol@stonegateinc.com
Source: Stonegate, Inc.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/116651
